Most Recent Articles by Tiffany Garbutt, PhD
Prevalence of Excess Body Weight-Related Cancer Varies Across the 50 US States, District of Columbia
Jan 11, 2019Statistics on excess body weight-related cancers across the United States and the District of Columbia, state-by-state.
9-Week Trastuzumab Course Not Noninferior to Standard Course for HER2+ Breast Cancer, But Does Offer a Benefit
Jan 10, 2019Although 9 weeks of adjuvant trastuzumab was not noninferior to the standard 1 year of trastuzumab, researchers were surprised by the difference they did find between the 2 treatment courses.
Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer
Jan 10, 2019In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.
Imported Doxorubicin Similar to US FDA-Approved Brand in Relapsed/Refractory Ovarian Cancer
Jan 09, 2019This retrospective analysis determined the effect of Doxil vs Lipodox brands of doxorubicin, used for the treatment of recurrent or refractory ovarian cancer.
No Benefit Achieved With Cytoreductive Therapy for Essential Thrombocythemia With Nonhigh Risk of Thrombosis
Dec 28, 2018A study with more than 2000 patient-years follow-up, researchers found cytoreductive therapy was not as effective in patients with ET who have lower risk for thrombosis.
More Articles by Tiffany Garbutt, PhD
HNC Survivors Continue to Experience Chronic Systemic Symptoms at 1 Year or More Posttreatment
Dec 26,2018Mini-Pools of IVIG Just as Effective as Standard IVIG in Pediatric Immune Thrombocytopenia
Dec 26,2018Beliefs About Medicine, Medicine Sensitivity Influence Patient Decisions on Tamoxifen Use
Dec 24,2018Prostate Cancer Screening, Treatment Information in YouTube Videos Unreliable, Inaccurate
Dec 24,2018Mechanical Shoulder Integrity Not Compromised After Breast-Conserving Surgery, Radiotherapy
Dec 17,2018Sign Up for Free e-newsletters
ONA Articles
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- NIH Establishes Educational Program on Genomics, Genetics for Oncology Nurses
- Less Diversity in PROM Systems Could Improve Assessing Their Practicality for Cancer Patients, Clinicians
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |